BUFFALO BIOMEDICAL
TECHNOLOGY Co., Ltd.
BUFFLO BIOMEDICAL
TECHNOLOGY
A pre-clinical-stage company offering novel lung lavage therapeutics.
Profile
Buffalo Biotech is a pre-clinical-stage company offering novel lung lavage therapeutics ("Vigor solution") for acute respiratory distress syndrome (ARDS). Buffalo Biotech is the first to develop a unique physical therapy method to overcome no pharmacologic therapy problem for ARDS. "Vigor solution" utilizes a non-specific adsorption method to effectively decrease cytokines in the lungs. The safety assessment of "Vigor solution" through pulmonary irrigation in mini-Pigs (168 days post Vigor administration) reoprt the "Vigor solution" was harmless. Severe ARDS animal studies demonstrated reductions 25% PMNL infiltration, 25% intra alveolar edema, and 50% mortality. We are seeking funding, to support us corporation with physician to treat ARDS patients by compassionate use. The "Vigor solution" not only can used in typical ARDS, but also COVID-19 ARDS.
Our Vision
New solution for prevention and treatment emergency patients in COVID-19 ARDS
Adult respiratory distress syndrome (ARDS)
Acute lung injury (ALI)
HELP ARDS PATIENTS BREATH AGAIN !
Buffalo Biomedical Technology Co. Ltd. is a start-up company to develop a novel "VIGOR lung irrigation solution" to quickly inhibit inflammation and relieve disease of acute lung injury (ALI), adult respiratory distress syndrome (ARDS) and COVID-19 ARDS. The "Vigor lung irrigation solution" has a nonspecific adsorption component that can clean lung and inhibit inflammation passway to decrease pulmonary edema, alveolar infiltrates to relieve acute respiratory distress syndrome (ARDS). To help ARDS and ALI patients to restore the function of the lungs for gas exchange, to breath and life again in short time.
Contact
2F., No. 1, Sec. 5, Zhongxiao E. Rd., Xinyi Dist., Taipei City 110410, Taiwan (R.O.C.)
110410台北市信義區忠孝東路五段1號2樓
Office +886-2-25174841
Mobile +886-926-129005